Michigan Could Receive Up To $ 800 Million In Landmark National Opioid Settlement, AG Office Says

(WXYZ) – Michigan could receive up to nearly $ 800 million in a national opioid settlement, the Michigan attorney general’s office said Thursday.

The multibillion-dollar settlement was reached with Johnson & Johnson and three pharmaceutical distributors: Cardinal Health, McKesson and AmerisourceBergen.

Related:

The AG’s office says Dana Nessel and other state attorneys general across the country have worked to hold businesses accountable for their role in helping fuel the growing opioid epidemic.

According to the office of the GA, only the national tobacco regulation of 1998 was higher than this regulation.

“When I ran for Attorney General, I made a commitment to do everything possible to help our residents in the state whose lives have been torn apart by the opioid epidemic. I am delighted to keep that promise,” Nessel said in a press release. “This historic settlement will help save lives and further address the current crisis, while ensuring that those who created this disaster pay for our collective recovery. For too long, local communities have borne the burden of tackling the opioid epidemic and have felt a stance on their cause was not listening. This settlement will provide much needed financial support for continued intervention, statewide treatment services and efforts, and eventual healing for Michigan families.

The overview of the injunction is as follows:

Demands Cardinal, McKesson and AmerisourceBergen, through court orders, to:

  • Establish an independent, centralized clearinghouse to provide the three distributors and state regulators with aggregated data and analysis on drug destination and frequency, thereby eliminating blind spots in the current systems used by distributors.
  • Use data-driven systems to detect suspicious opioid orders from client pharmacies.
  • Terminate the ability of customer pharmacies to receive shipments and report these businesses to state regulatory authorities when they show certain signs of diversion.
  • Prohibit shipping and report suspicious opioid orders.
  • Prohibit sales staff from influencing decisions about identifying suspicious opioid orders.
  • Require senior company officials to engage in regular monitoring of anti-hijacking efforts.

Demands Johnson & Johnson, through court orders, to:

  • Stop selling opioids.
  • Do not fund or provide grants to third parties for the promotion of opioids.
  • Don’t pressure opioid-related activities.
  • Share clinical trial data as part of the Yale University Open Data Access Project.

You can read more here.


Source link